ANG Lifesciences Reports Q2 FY2026 Loss, Appoints New Cost Auditor

ANG Lifesciences India Limited, a pharmaceutical company, has released its financial results for the second quarter of fiscal year 2026, revealing a narrowed loss but decreased revenue compared to the same period last year.

Financial Performance

The company's financial performance for Q2 FY2026 and the first half of the fiscal year is summarized in the table below:

ANG Lifesciences' net loss for Q2 FY2026 stood at ₹79.98 lakh, showing an improvement from the ₹107.39 lakh loss reported in the same quarter of the previous fiscal year. However, revenue from operations declined to ₹2597.05 lakh from ₹3215.88 lakh year-over-year.

For the first half of FY2026, the company reported a net loss of ₹158.71 lakh, compared to ₹383.92 lakh in the corresponding period of the previous year.

Board Meeting and Auditor Appointment

The Board of Directors of ANG Lifesciences India Limited convened on November 14, 2025, to approve the unaudited financial results for Q2 and H1 FY2026. The meeting, which commenced at 05:00 PM, also addressed other corporate matters.

In a significant development, the Board approved the appointment of M/s Shreya Sahu & Associates as the Cost Auditor for the fiscal year 2025-26. This appointment underscores the company's commitment to maintaining robust financial oversight and compliance with regulatory requirements.

Regulatory Compliance

The financial results were prepared in accordance with Indian Accounting Standards and have undergone a limited review by the company's statutory auditors, M/s Khurana Sharma & Co. This review process ensures compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

ANG Lifesciences continues to navigate challenges in the pharmaceutical sector, as reflected in its financial performance. The company's efforts to streamline operations and reduce losses are evident, though revenue pressures persist.